First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

• Status: Completed
• Trial end date: 2013-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered ALS-002200 in healthy volunteers (HV) and subjects with chronic hepatitis C (CHC) genotype 1 infection.

Part 1 will assess single ascending dosing pharmacokinetics and safety in HV. Part 2 will assess food effects on pharmacokinetics in HV. Part 3 will assess multiple ascending dosing pharmacokinetics and safety in subjects with CHC genotype 1 infection.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alios Biopharma Inc.
• Collaborator: Vertex Pharmaceuticals Incorporated

Criteria

Inclusion Criteria:

• Subject has provided written consent.

• In the investigator's opinion, the subject is able to understand and comply with protocol requirements, instructions, and protocol stated restrictions and is likely to complete the study as planned.

• Subject is in good health as deemed by the investigator.

• Creatinine clearance of greater than 50 mL/min (Cockcroft-Gault)

• Male or female, 18-55 years of age for HV and 18-65 years of age for subjects with CHC.

• Body mass index (BMI) 18-32 kg/m2 inclusive for HV and 18-36 kg/m2 for subjects with CHC, minimum weight 50 kg in both populations.

• A female is eligible to participate in this study if she is of non childbearing potential.

• If male, subject is surgically sterile or practicing specific forms of birth control.

Additional inclusion criteria for subjects with CHC genotype 1 infection:

• Positive HCV antibody and a positive HCV RNA at screening.

• Documentation of CHC infection for greater than 6 months at screening

• CHC genotype 1 infection at screening

• HCV RNA viral load ≥ 105 and ≤108 IU/mL using a sensitive quantitative assay.

• Liver biopsy within two years or Fibroscan evaluation within 6 months prior to screening that clearly excludes cirrhosis. Fibroscan liver stiffness score must be < 12 kPa.

• Absence of hepatocellular carcinoma as indicated by an ultrasound scan conducted during screening

• No prior treatment for CHC

• Absence of history of clinical hepatic decompensation.

• Laboratory values include:

• Prothrombin time < 1.5x ULN

• Platelets > 120,000/mm3

• Albumin > 3.5 g/dL, bilirubin < 1.5 mg/dL at screening (subjects with documented Gilbert's disease allowed).

• Serum alanine aminotransferase (ALT) concentration < 5 x ULN

• Alpha Fetoprotein (AFP) concentrations ≤ ULN. If AFP is ≥ ULN, absence of a hepatic mass must be demonstrated by ultrasound within the screening period.

Exclusion Criteria:

• Clinically significant cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder.

• Positive test for HAV IgM, HBsAg, HCV Ab (HV only), or HIV Ab.

• Abnormal screening laboratory results that are considered clinically significant by the investigator.

• Drug allergy such as, but not limited to, sulfonamides and penicillins, including those experienced in previous trials with experimental drugs.

• Participation in an investigational drug trial or having received an investigational vaccine within 30 days or 5 half lives (whichever is longer) prior to study medication.

• Clinically significant blood loss or elective blood donation of significant volume.

• For healthy subjects, history of regular use of tobacco.

• The subject has a positive pre-study drug screen.

• Laboratory abnormalities including:

• Thyroid Stimulating Hormone (TSH) > ULN

• Hematocrit < 34 %

• White blood cell counts < 3,500/mm3